Hopantomide in pediatric neurological practice: outlooks

Hopantomide® is a drug containing calcium salt of hopantenic acid. The drug is registered and produced in Russia (Usolye-Siberian Chemical Pharmaceutical Factory) with the use of own raw materials and goes through a full production cycle, which guarantees quality control at every stage. Hopantomide belongs to nootropics and has neurometabolic, neuroprotective, and neurotrophic properties, as well as anticonvulsant action. According to the package insert and results of the studies evaluating the efficacy of hopantenic acid, Hopantomide has a number of positive therapeutic effects. It increases brain resistance to hypoxia and toxic substances, stimulates anabolic processes in neurons, improves mental and physical performance, combines moderate sedative action with mild stimulating effect, reduces motor excitability with simultaneous regulation of behavior, improves the metabolism of gamma-aminobutyric acid and normalizes its level in individuals with chronic alcohol intoxication and after alcohol withdrawal, has anxiolytic and thymoleptic properties, inhibits the abnormal bladder reflex and detrusor tone. This ensures high efficacy of Hopantomide in the treatment of various nervous diseases in different age groups. In our opinion, the combination of various positive effects of just one drug can significantly reduce the pharmacological burden. In this review, we discuss well-known and potential mechanisms of action, indications for its use with a focus on Hopantomide benefits in pediatric neurological practice, and studies evaluating the efficacy of hopantenic acid in clinical practice. Particular attention is paid to the possibilities of its use in children, including those with attention deficit hyperactivity disorder and developmental delay, as well as the part of combination therapy for epilepsy together with antiepileptic drugs.

Drugs containing hopantenic acid are well tolerated by patients, including children who receive it for a long time.

1. Yokoyama U., Iwatsubo K., Umemura M. et al. The prostanoid EP4 receptor and its signaling pathway. Pharmacol Rev 2013;65(3):1010–52.

2. Balkanskaya S.V., Kuzenkova L.M., Studenikin V.M., Maslova O.I. Rolandic epilepsy in children: treatment of cognitive disorders. Voprosy sovremennoy pediatrii = Current Pediatrics 2008;7(5):34–8. (In Russ.).

3. Balkanskaya S.V., Studenikin V.M., Kuzenkova L.M. et al. Cognitive disorders and their management in children with epilepsy. Praktika pediatra = Pediatrician’s Practice 2008;(3):24–7. (In Russ.).

4. Balkanskaya S.V., Studenikin V.M., Kuzenkova L.M. et al. Nootropics in the correction of cognitive functions in children with epilepsy. Voprosy sovremennoy pediatrii = Current Pediatrics 2007;6(2):92–6. (In Russ.).

5. Gekht A.B., Kanaeva L.S., Avedisova A.S. et al. Utility of rac-hopantenic acid in comprehensive treatment of anxiety and depressive disorders in patients with chronic cerebral ischemia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2016;116(11):45–57. (In Russ.). DOI: 10.17116/jnevro201611611145-57.

6. Hopantenic acid. Reference list of medicines. Moscow, 2014. (In Russ.).

7. Hopantomide: medication package insert. Vidal Reference Guide of Medicines. Available at: https://www.vidal.ru/drugs/hopantomide/. (In Russ.).

8. Gromova O.A., Torshin I.Yu., Limanova O.A. et al. Neurotropic, anti-inflammatory, and antitumor properties of hopantenic acid according to the results of chemo-infor matic analysis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. Special issues 2015;115(5– 2):61–71. (In Russ.). DOI: 10.17116/jnevro20151155261-71.

9. Guzeva V.I., Guzeva V.V., Guzeva O.V. et al. Therapeutic effect of hopantenic acid (Pantogam) in children with epilepsy and speech disorders. Pediatriya = Pediatrics 2015;94(3):148–57. (In Russ.).

10. Guzeva V.I., Korostovtsev D.D., Fomina M.Yu. et al. Experience in the use of hopantenic acid (syrup) in children with epilepsy, cognitive disorders, and attention deficit hyperactivity disorder. Voprosy sovremennoy pediatrii = Current Pediatrics 2007;6(1):101–4. (In Russ.).

11. Zavadenko N.N., Kozlova E.V., Shchederkina I.O. et al. Speech disorders in children and epileptiform activity on EEG. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. Special issues 2014;114(4–2):11–7. (In Russ.).

12. Zavadenko N.N. Disorders of neuropsychiatric development in children with epilepsy. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2016;8(1):50–4. (In Russ.). DOI: 10.17749/2077-8333.2016.8.1.050-054.

13. Zavadenko N.N. Attention deficit hyperactivity disorder: current principles of diagnosis and treatment. Voprosy sovremennoy pediatrii = Current Pediatrics 2014;13(4):48–53. (In Russ.). DOI: 10.15690/vsp.v13i4.1084.

14. Zavadenko N.N., Kozlova E.V. Nootropics for developmental dysphasia in children. Voprosy prakticheskoy pediatrii = Clinical Practice in Pediatrics 2013;8(5):24–8. (In Russ.).

15. Zavadenko N.N., Kuvichinskaya A.V., Lebedeva T.V. et al. Spoken and written language disorders in children. Possibilities of pharmacological correction (methodological guide for students and doctors). Moscow, 2003. 60 p. (In Russ.).

16. Zavadenko N.N., Suvorinova N.Yu. Attention deficit hyperactivity disorder: choosing the optimal duration of pharmacotherapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2011;111(10):28–32. (In Russ.).

17. Zavadenko N.N., Suvorinova N.Yu., Vakula I.N. et al. Pharmacotherapy of attention deficit hyperactivity disorder in children: results of a multicenter, double-blind, placebo-controlled trial of hopantenic acid. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2017;117(5):39–45. (In Russ.). DOI: 10.17116/jnevro20171175139-45.

18. Zavadenko N.N., Suvorinova N.Yu., Zavadenko A.N. Attention deficit hyperactivity disorder in children: efficacy of pharmacotherapy with hopantenic acid. Voprosy prakticheskoy pediatrii = Clinical Practice in Pediatrics 2018;13(2):11–8. (In Russ.).

19. Zykov V.P. Tics and Tourette syndrome in children. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2020;120(5):116–24. (In Russ.). DOI: 10.17116/jnevro2020120051116.

20. Kanaeva L.S., Vazagaeva T.I., Yastrebova V.V. Outlooks of therapy with Pantogam active in patients with asthenic disorders. Psikhiatriya i psikhofarmakoterapiya = Psychiatry and Psychopharmacotherapy 2009;11(6):34–9. (In Russ.).

21. Kuzenkova L.M., Maslova O.I. Pantogam in the treatment of neurological diseases in children. Praktika pediatra = Pediatrician’s Practice 2007;(1):19–22. (In Russ.).

22. Kupriyanova T.A., Koren E.V., Alabusheva N.N. Strategy for improving the effectiveness of psychopharmacological treatment of hyperkinetic behavior disorder using pantogam. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. Special issues 2017;117(11–2): 75–9. (In Russ.). DOI: 10.17116/jnevro201711711275-79.

23. Madzhidova E.N., Solikhzoda A.A., Maksudova Kh.N. Clinical and neurological characteristics of patients with drug-resistant epilepsy and optimization of therapy. Epilepsiya i paroksizmalnye sostoyaniya = Epilepsy and Paroxysmal Conditions 2019;11(1):46–52. (In Russ.). DOI: 10.17749/2077-8333.2019.11.1.46-52.

24. Maslova O.I. Correction of cogni tive disorders in children during the school year. Praktika pediatra = Pediatrician’s Practice 2006;(9). (In Russ.).

25. Maslova O.I., Studenikin V.M., Balkanskaya S.V., Kuzenkova L.M. Efficacy of Pantogam syrup 10 % (hopantenic acid) in the management of cognitive disorders in children. Voprosy sovremennoy pediatrii = Current Pediatrics 2004;3(4):2–6. (In Russ.).

26. Maslova O.I., Shelkovskiy V.I. Pantogam and pediatric psychoneurology. In: Pantogam. Twenty-year experience of its use in psychoneurological practice. Moscow, 1998. Pp. 50–53. (In Russ.).

27. Medvedev V.E., Frolova V.I., Barsegyan T.V. Therapy of non-psychotic mental disorders in patients planning plastic surgery. Rossiyskaya stomatologiya = Russian Dentistry 2013;6(4):15–25. (In Russ.).

28. Ostroumova O.D. Utility of D- and L-hopantenic acid in the treatment of cognitive and anxiety disorders in patients with essential arterial hypertension. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2018;118(10):115–21. (In Russ.). DOI: 10.17116/jnevro2018118101115.

29. Panteleeva M.V., Borisova M.N., Ovezov A.M. et al. Postoperative cognitive dysfunction in clinical practice of a pediatrician. Praktika pediatra = Practice of the Pediatrician 2017:23–8. (In Russ.).

30. Skripchenko N.V., Ivanova G.P., Skripchenko E.Yu. et al. Efficacy of antiviral therapy and serotherapy of tick-borne encephalitis in children. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. Special issues 2019;119(7–2):40–51. (In Russ.). DOI: 10.17116/jnevro201911907240.

31. Stepanchenko O.A. Pantogam: correction of CNS dysfunction at any age. Meditsinskiy vestnik = Medical Bulletin 2006;31(374):12. (In Russ.).

32. Studenikin V.M., Shelkovskiy V.I., Balkanskaya S.V. Use of hopantenic acid in neuropediatric practice: 30 years of experience and prospects. Praktika pediatra = Pediatrician’s Practice 2009;(3):47–51. (In Russ.).

33. Studenikin V.M., Shelkovskiy V.I., Tursunkhuzhaeva S.Sh. et al. Pantogram (hopantenic acid): traditional and new applications in pediatric neurological practice. Praktika pediatra = Pediatrician’s Practice 2010;5:22–5. (In Russ.).

34. Sukhotina N.K., Kryzhanovskaya I.L., Kupriyanova T.A. Pantogam as a drug for preventing borderline disorders in children. Nauchno-prakticheskiy zhurnal psikhiatrii, psikhologii, psikhoterapii i smezhnykh distsiplin = Research and Practical Journal of Psychiatry, Psychology, Psychotherapy, and Related Disciplines 2004;(2). (In Russ.).

35. Sukhotina N.K. Pantogram as a treatment for borderline neuropsychiatric disorders. Meditsinskiy vestnik = Medical Bulletin 2006;11(14):1–4. (In Russ.).

36. Sukhotina N.K., Konovalova V.V., Kryzhanovskaya I.L., Kupriyanova T.A. Efficacy of pantogam in the treatment of hyperkinetic disorders in children. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2010;110(12):24–8. (In Russ.)].

37. Tomilova A.Yu., Namazova L.S., Kuzenkova L.M. et al. Effect of comprehensive therapy on the quality of life of children with allergic rhinitis. Voprosy sovremennoy pediatrii = Current Pediatrics 2007;4(2):67–71. (In Russ.).

38. Chutko L.S., Surushkina S.Yu., Yakovenko E.A. et al. Efficacy of hopantenic acid in the treatment of fatigue in primary school children. Voprosy prakticheskoy pediatrii = Clinical Practice in Pediatrics 2018;13(3):62–5. (In Russ.). DOI: 10.20953/1817-7646-2018-3-61-65.